Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: NeuroVax, Immune Response Corp.

Cynthia L Darlington1

  • 1University of Otago Medical School, Department of Pharmacology and Toxicology, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz

Current Opinion in Molecular Therapeutics
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Animal studies linking the vestibular system and memory: Aotearoa/New Zealand's contribution.

Journal of the Royal Society of New Zealand·2025
Same author

Sexual dimorphism in vestibular function and dysfunction.

Journal of neurophysiology·2019
Same author

Video head impulse in comparison to caloric testing in unilateral vestibular schwannoma.

Acta oto-laryngologica·2016
Same author

The Effects of Complete Vestibular Deafferentation on Spatial Memory and the Hippocampus in the Rat: The Dunedin Experience.

Multisensory research·2015
Same author

The effects of acute stress-induced sleep disturbance on acoustic trauma-induced tinnitus in rats.

BioMed research international·2014
Same author

Galvanic vestibular stimulation impairs cell proliferation and neurogenesis in the rat hippocampus but not spatial memory.

Hippocampus·2014

NeuroVax, a novel vaccine for multiple sclerosis, combines three T-cell receptor peptides. This investigational treatment is currently in phase II clinical trials to assess its efficacy and safety.

Area of Science:

  • Neuroimmunology
  • Vaccine Development
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease targeting the central nervous system.
  • Current MS treatments primarily focus on managing symptoms and modulating the immune response.
  • There is a need for disease-modifying therapies that address the underlying autoimmune mechanisms in MS.

Purpose of the Study:

  • To evaluate NeuroVax, a novel therapeutic vaccine, as a potential treatment for multiple sclerosis.
  • To assess the safety and efficacy of a combination T-cell receptor peptide vaccine in individuals with MS.
  • To investigate the immunomodulatory effects of NeuroVax in the context of MS.

Main Methods:

  • NeuroVax is a combination vaccine comprising three T-cell receptor peptides (BV5S2, BV6S5, and BV13S1).

Related Experiment Videos

  • The vaccine is formulated with incomplete Freund's adjuvant.
  • The study involves ongoing phase II clinical trials to evaluate the vaccine's therapeutic potential.

    • Main Results:

    • Phase II clinical trials are currently underway to determine the efficacy and safety of NeuroVax.
    • Preliminary data from ongoing trials will inform the potential of NeuroVax as an MS treatment.
    • The study aims to elucidate the immune response modulation induced by the vaccine.

    Conclusions:

    • NeuroVax represents a promising therapeutic strategy for multiple sclerosis.
    • Further clinical evaluation is necessary to establish the long-term benefits and safety profile of NeuroVax.
    • The development of T-cell receptor-based vaccines offers a novel approach to treating autoimmune conditions like MS.